Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics
Recent annotation of the human transcriptome revealed that only 2 % of the genome encodes proteins while the majority of human genome is transcribed into noncoding RNAs. Although we are just beginning to understand the diverse roles long noncoding RNAs (lncRNAs) play in molecular and cellular processes, they have potentially important roles in human development and pathophysiology. However, targeting of RNA by traditional structure-based design of small molecule inhibitors has been difficult, due to a lack of understanding of the dynamic tertiary structures most RNA molecules adopt. Antisense oligonucleotides (ASOs) are capable of targeting specific genes or transcripts directly through Watson–Crick base pairing and thus can be designed based on sequence information alone. These agents have made possible specific targeting of “non-druggable targets” including RNA molecules. Here we describe how ASOs can be applied in preclinical studies to reduce levels of lncRNAs of interest.
Key wordsAntisense oligonucleotide Control ASO Non-druggable targets Off-target RNA therapeutics Target reduction RNase H qRT-PCR Transfection Free uptake
We thank XueHai Liang for discussion and sharing unpublished data. We are grateful to Lauren Elder for editorial assistance.
- 6.Meng L, Ward AJ, Chun S, Bennett CF, Beaudet al, Rigo F (2014) Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature 518(7539):409–12Google Scholar
- 22.Henry SP, Geary RS, Yu R, Levin AA (2001) Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Current Opin Investig Drugs 2:1444–1449Google Scholar
- 28.Hong DS, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, LeeSJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Monia BP, and MacLeod AR (2015). AZD9150, a nextgeneration antisense oligonucleotide Inhibitor of STAT3, with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med (in press)Google Scholar
- 35.Ostergaard ME, Southwell AL, Kordasiewicz H, Watt AT, Skotte NH, Doty CN et al (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res 41:9634–9650CrossRefPubMedPubMedCentralGoogle Scholar